In Q4 2025, Vericel delivered 23% total revenue growth driven by MACI performance, achieved a record 79% gross margin, and increased net income and adjusted EBITDA compared to the prior year quarter.

Vericel delivered a solid second quarter in 2025, achieving record total revenue and MACI revenue. The company saw substantial growth in adjusted EBITDA and improved gross margin, alongside positive trends in key performance indicators for its MACI Arthro launch and burn care products.

Vericel reported record first quarter MACI and total revenue, driven by continued strength in MACI Arthro launch. The company reaffirmed full-year revenue guidance and raised profitability guidance.

Vericel reported a strong fourth quarter and full-year 2024, with total net revenue for the quarter increasing by 16% to $75.4 million. The company saw growth in MACI and Burn Care revenues, along with a record gross margin of 78% and net income growth of 52% to $19.8 million.

Vericel Corporation reported a strong third quarter in 2024, marked by a 27% increase in total revenue to $57.9 million. The company achieved a gross margin of 72% and an 84% growth in adjusted EBITDA. Key highlights include the FDA approval and commercial launch of MACI Arthro and a raised full-year profitability guidance.

Vericel Corporation reported a strong second quarter with record revenue driven by MACI and NexoBrid growth. The company raised its full-year profitability guidance due to strong performance.

Vericel Corporation reported a 25% increase in total revenue to $51.3 million for Q1 2024. MACI revenue grew by 18% to $40.2 million, and Burn Care revenue increased by 63%. The company's adjusted EBITDA increased by 325% and raised its full-year revenue guidance to $238-$242 million.

Vericel Corporation reported a 23% increase in total net revenue to $65.0 million for the fourth quarter of 2023. Net income grew by 119% to $13.0 million, and non-GAAP adjusted EBITDA increased by 50% to $22.3 million. The company provided full-year 2024 revenue guidance of $237 to $241 million.

Vericel Corporation reported a record third quarter revenue of $45.6 million, representing an 18% growth compared to the prior year. The company raised its full-year 2023 revenue guidance to $192.5-197.5 million.

Vericel Corporation reported a record second quarter with total revenue of $45.9 million, a 24% increase compared to the prior year. The company raised its full-year 2023 revenue guidance to $190-197 million.

Vericel Corporation reported a strong start to 2023 with record first-quarter total revenue of $41 million, driven by a 32% increase in MACI revenue to $34.2 million. The company raised its full-year 2023 revenue guidance to $184-$192 million. They also reported a net loss of $7.5 million, or $0.16 per diluted share, and a non-GAAP adjusted EBITDA of $1.7 million.

Vericel Corporation reported a record fourth quarter with total revenue of $52.7 million and a 31% net income growth. The company also provided full-year 2023 total revenue guidance of $180 to $188 million, with MACI revenue of $152 to $156 million.

Vericel Corporation reported a strong third quarter with a 12% increase in total net revenue to $38.6 million. MACI net revenue increased by 30% to $31.0 million. The company reported a net loss of $6.6 million, or $0.14 per share, and a non-GAAP adjusted EBITDA of $3.3 million.

Vericel Corporation reported a decrease in total net revenue to $37.0 million for the second quarter of 2022, with MACI net revenue reaching $28.6 million. The company experienced a net loss of $9.0 million, or $0.19 per share, and achieved a non-GAAP adjusted EBITDA of $2.8 million.

Vericel Corporation reported a 4% increase in total net revenue for Q1 2022, reaching $36.1 million compared to $34.6 million in Q1 2021. The company experienced a net loss of $7.1 million, or $0.15 per share, compared to a net loss of $3.3 million, or $0.07 per share, in the same quarter of the previous year.

Vericel reported a 5% increase in total net revenue for the fourth quarter of 2021, reaching $47.6 million. Net income was $4.5 million, or $0.09 per share, and non-GAAP adjusted EBITDA was $12.8 million.

Vericel Corporation reported a 7% increase in total net revenue for the third quarter of 2021, reaching $34.5 million compared to $32.3 million in the third quarter of 2020. Despite the revenue growth, the company experienced a net loss of $4.9 million, or $0.11 per share, a shift from the net income of $3.6 million, or $0.08 per share, reported in the same quarter of the previous year.

Vericel Corporation reported a significant increase in revenue for the second quarter of 2021, with total net revenue increasing by 97% to $39.5 million. The company also raised its full-year 2021 revenue guidance to $168-$171 million. Net loss decreased to $3.8 million, or $0.08 per share, and non-GAAP adjusted EBITDA was $7.8 million, or 20% of net revenue.

Vericel Corporation reported a 30% increase in total net revenue to $34.6 million for the first quarter of 2021, driven by strong performance in both sports medicine and burn care franchises. The company raised its full-year 2021 revenue guidance to $165 - $168 million and reported a net loss of $3.3 million, or $0.07 per share.

Vericel Corporation reported a 15% increase in total net revenue to $45.2 million for the fourth quarter of 2020, with a net income of $12.2 million. The company's full-year 2021 total revenue is expected to grow 30%-32% to approximately $161 to $164 million.

Vericel Corporation reported a 6% increase in total net revenues, reaching $32.3 million for the third quarter of 2020, compared to $30.5 million in the third quarter of 2019. The company's net income also increased to $3.6 million, or $0.08 per share, compared to $3.5 million, or $0.07 per share, for the third quarter of 2019.

Vericel Corporation reported a total net product revenue of $20.0 million for Q2 2020, a decrease compared to $26.2 million in Q2 2019. The company experienced a net loss of $8.3 million, or $0.18 per share, compared to a net loss of $19.8 million, or $0.45 per share, in the same quarter of the previous year. As of June 30, 2020, the company's cash and investments totaled $80.9 million with no debt.

Vericel Corporation reported a 22% increase in total net product revenues to $26.7 million for the first quarter of 2020, compared to $21.8 million in the first quarter of 2019. However, the company's net loss increased to $4.7 million, or $0.10 per share, compared to a net loss of $2.8 million, or $0.07 per share, for the first quarter of 2019.

Vericel Corporation reported financial results for Q4 and full year 2019. The company's total net product revenues increased by 26% to $39.4 million compared to Q4 2018. Net income was $9.5 million, or $0.20 per share, compared to $5.2 million, or $0.11 per share, in the fourth quarter of 2018.